Loop played a dangerous game with INTEL! Insider trading? RICO?
https://www. smarteranalyst.com/2017/10/27/intel-corporation-intc-gets-price-target-boost-loop-capital-heres/
Betsy knew about the flaws they had to announce…
>Intel Corporation (NASDAQ:INTC) shares are rising 5% after quite a massive, “impressive” third quarter masterful serve, leading Loop Capital analyst Betsy Van Hees to commend the chip maker for “firing on all cylinders.”
Now imagine if she purchased AMD stock, or had other people buy it based on that insider knowledge… HMMMNNNNNN
COULD THEY BE THAT STUPID?
Is this too early to start looking in to BIOGEN?
The Board of Biogen
Mr. Bruce R. Ross (Chairman)
Bruce R. Ross was appointed Chairman of the Board in January 2006. Mr. Ross is currently President of Cancer Rx, a healthcare-consulting firm. Immediately prior to launching Cancer Rx, Mr. Ross was Chief Executive Officer of the National Comprehensive Cancer Network, an association of 15 of the largest cancer centers in the United States. He previously held senior management positions, during a 27-year career, at Bristol-Myers Squibb, including Senior Vice President, Policy, Planning and Development, Bristol-Myers Squibb Pharmaceutical Group and President, Bristol-Myers Squibb U.S. Pharmaceutical Group. He received his B.S. from Syracuse University and later was a Bristol-Myers Scholar at the Yale School of Organization and Management. Mr. Ross began serving as a Director of IDEC Pharmaceuticals in 1997. Tom Harkin is asking Brook Byers to call
Mr. James C. Mullen (CEO)
James C. Mullen is President and Chief Executive Officer of Biogen Idec and has served in these positions since the merger in November 2003. Mr. Mullen joined Biogen Inc. in 1989. He was named Chief Executive Officer in 2000 and Chairman in 2002. Prior to being named CEO and Chairman, he also held the positions of President and Chief Operating Officer (1999-2000); Vice President, International (1996-1999); Vice President, Operations (1992-1996); and Director, Facilities and Engineering (1989-1992). Mr. Mullen is a member of the Board of Directors of PerkinElmer Inc. and the Biomedical Science Careers Program Inc. He holds a B.S. in Chemical Engineering from Rensselaer Polytechnic Institute and an M.B.A. from Villanova University.
https:// wikileaks.org/podesta-emails/emailid/12880
Stelios is a Phd. who worked at Cowen, Cowen became Wedbush (Betsy Van Hees company). Cowen is deep with Podesta.
Stelios Papadopoulos, Ph.D.
Stelios Papadopoulos, Ph.D., retired as Vice Chairman of Cowen & Co. LLC in August 2006 after six years as an investment banker with the firm, where he focused on the biotechnology and pharmaceutical sectors. Prior to joining Cowen & Co., he spent 13 years as an investment banker at PaineWebber Inc., where he was most recently Chairman of PaineWebber Development Corp., a PaineWebber subsidiary focusing on biotechnology. Dr. Papadopoulos is affiliated with New York University Medical Center as an Adjunct Associate Professor of Cell Biology. Dr. Papadopoulos is a co-founder and Chairman of the board of Exelixis Inc., a drug discovery and development company. He is also co-founder and member of the boards of directors of Anadys Pharmaceuticals Inc., a drug discovery and development company, and Cellzome Inc., a privately held drug discovery company. He is a member of the board of directors of Neuronyx Inc. and vice chairman of the board of directors of BG Medicine Inc., both privately held life sciences companies. In the not-for-profit sector, Dr. Papadopoulos is co-founder and Chairman of Foundation Sante, a member of the board of visitors of Duke University Medical Center and a member of the board of directors of the National Marrow Donor Program. Dr. Papadopoulos began serving as a director of Biogen Idec in 2008. Gail Furman is asking John Sexton to call
tell us more